This meeting took place in 2019


Here are the related meetings in 2020:
Brain Therapeutics: Disruptive Technologies and Opportunities (Q3)
Cellular Pathways Driving Neurodegeneration and Future Therapeutics (Z6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)


Organizer(s) Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage
June 16—20, 2019
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Feb 13, 2019
Abstract Deadline: Mar 13, 2019
Scholarship Deadline: Feb 13, 2019
Discounted Registration Deadline: Apr 16, 2019

Sponsored by BioLegend, Inc., Biogen, BlueRock Therapeutics, Genentech, Inc., Ionis Pharmaceuticals, Inc., Roche and Takeda Pharmaceutical Company Limited


Summary of Meeting:
The global burden of neurodegenerative disease is staggering and growing at an alarming rate as the population ages. While Alzheimer’s disease and related dementias, as well as, Parkinson’s disease and related disorders, account for the majority of those afflicted, there are also less common but equally devastating diseases. Technical and conceptual advances are revealing disease mechanisms and providing new therapeutic opportunities. Misfolded proteins have been understood to be at the center of neurodegenerative diseases but recently there is an appreciation that these misfolded proteins may serve as seeds to template the misfolding of normal proteins, that transmission of these seeds may underlie disease progression, and that there may be different strains of these seeds with differential toxicities. Biophysical analysis of these proteins reveals a role for phase transition and liquid demixing of these intrinsically disordered proteins. Synaptic loss is an important feature of neurodegeneration which may occur long before neuronal loss, but be critically important in disease presentation and loss of function. Glia and immune activation contribute to neurodegeneration and synaptic loss, and must be understood and controlled if the disease process is to be tempered or stopped. This conference aims to address the current state of knowledge in these emerging area and to provide advanced discussion of these topics; the opportunity for interaction between scientists from different fields of research will foster new collaborations that may lead to new therapeutic opportunities to combat the coming crisis and provide medical care for those suffering from neurodegenerative diseases.

View Meeting Program

Scholarships/Awards

Burroughs Wellcome Fund ECITA Scholarship Recipients

Amy L. Brewster
Purdue University, USA

Joaquin N. Lugo
Baylor University, USA

Keystone Symposia Future of Science Fund Scholarship Recipients

Daniel Heinzer
University of Zurich, Switzerland

Evan T. Lester
University of Colorado, USA

National Institute of Neurological Disorders and Stroke (NINDS) Scholarship Recipients

Anastasia Efthymiou
Icahn School of Medicine at Mount Sinai, USA

Amanda Engstrom
Emory University, USA

Ryan Douglas Hallam
University of Guelph, Canada

Timothy J. Hark
Northwestern University, USA

Xuyuan Kuang
Rutgers University, USA

Britney N. Lizama
University of Pittsburgh, USA